Essential Tremor (ET) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Essential Tremor (ET) Emerging Therapy and TPP Insights

Thelansis's "Essential Tremor (ET) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Essential Tremor (ET) Overview

Essential tremor (ET) is one of the most common adult movement disorders, characterized as a chronic, progressive neurological condition manifesting primarily as a symmetric kinetic and postural tremor. It predominantly affects the upper extremities, though the head, voice, and lower limbs can be involved. Unlike Parkinson's disease, the tremor is typically absent at rest and worsens during voluntary, goal-directed movements, significantly impairing activities of daily living like writing, eating, and drinking. Pathophysiology is linked to dysfunction within the cerebello-thalamo-cortical network, often with a strong autosomal dominant family history. Diagnosis remains clinical, based on history and examination, while ruling out secondary causes like hyperthyroidism or medication effects. Management in 2026 relies on oral pharmacotherapy, primarily propranolol or primidone, as frontline choices. For medically refractory, severe cases, the therapeutic paradigm emphasizes advanced stereotactic interventions, specifically MRI-guided focused ultrasound (MRgFUS) thalamotomy or deep brain stimulation targeting the ventral intermediate nucleus of the thalamus to restore functional independence.

Key Highlights

• The diagnosed ET population is large and steadily growing, supported by aging demographics and increased awareness, with low-to-mid single digit CAGR (2-3%) over the forecast period.
• ET shows a higher prevalence in older age groups, with the majority of diagnosed cases concentrated in patients aged >=55 years, reflecting age-related disease progression.
• Despite high prevalence, diagnosis and treatment rates remain suboptimal, with a significant proportion of patients either untreated or managed conservatively.
• The treatment landscape is heavily dominated by generic therapies, with:
• Beta-blockers accounting for the largest share (30-35%)
• Anticonvulsants contributing 25-30%
• Remaining share distributed across adjunct therapies
• Treatment patterns indicate a high reliance on symptomatic control, with limited use of advanced or interventional therapies.
• Emerging therapies (e.g., next-generation small molecules and neuromodulation approaches) are expected to gradually improve treatment outcomes but remain limited in near-term impact.

Market Overview

• The ET market demonstrates moderate growth (3-5% CAGR) over the forecast period, driven by increasing diagnosis rates and gradual therapy uptake.
• The market remains predominantly generic-driven, with: >80% of revenue derived from low-cost oral therapies and Limited pricing power across established drug classes
• Beta-blockers (primarily propranolol) remain the leading segment, contributing 30%+ of total market share, followed by primidone and other anticonvulsants (40% combined).
• Gabapentin and metoprolol contribute a steady mid-tier share, with incremental growth aligned with patient volume expansion.
• Pipeline and novel therapies (e.g., ulixacaltamide) show high relative growth (>10-12% CAGR) but from a low base, gradually increasing their market share toward the later years.
• Botulinum toxin therapies represent a small but growing segment (8-10% CAGR), particularly in refractory patients.
• Overall market growth is constrained by: High generic penetration, Lack of disease-modifying therapies, Continued reliance on first-line symptomatic treatments

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Praxis Precision Medicines
• Sage Therapeutics
• Jazz Pharmaceuticals
• GE Healthcare
• AbbVie